Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

NASDAQ:NMRA - Nasdaq - US6409791000 - Common Stock - Currency: USD

1.8  +0.09 (+5.26%)

After market: 1.8 0 (0%)

Fundamental Rating

2

Taking everything into account, NMRA scores 2 out of 10 in our fundamental rating. NMRA was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NMRA as it has an excellent financial health rating, but there are worries on the profitability. NMRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NMRA has reported negative net income.
NMRA had a negative operating cash flow in the past year.
In the past 5 years NMRA always reported negative net income.
NMRA had a negative operating cash flow in each of the past 5 years.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

NMRA has a worse Return On Assets (-83.31%) than 73.51% of its industry peers.
NMRA's Return On Equity of -91.57% is in line compared to the rest of the industry. NMRA outperforms 42.16% of its industry peers.
Industry RankSector Rank
ROA -83.31%
ROE -91.57%
ROIC N/A
ROA(3y)-44.51%
ROA(5y)N/A
ROE(3y)-47.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

NMRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for NMRA has been increased compared to 1 year ago.
NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.69, we must say that NMRA is in the distress zone and has some risk of bankruptcy.
NMRA has a Altman-Z score (0.69) which is in line with its industry peers.
There is no outstanding debt for NMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.69
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 10.98 indicates that NMRA has no problem at all paying its short term obligations.
NMRA has a Current ratio of 10.98. This is amongst the best in the industry. NMRA outperforms 84.32% of its industry peers.
NMRA has a Quick Ratio of 10.98. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.98, NMRA belongs to the top of the industry, outperforming 84.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.98
Quick Ratio 10.98
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

NMRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.80%.
EPS 1Y (TTM)-4.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.5%
EPS Next 2Y3.54%
EPS Next 3Y2.94%
EPS Next 5Y13.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.54%
EPS Next 3Y2.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (2/21/2025, 8:00:01 PM)

After market: 1.8 0 (0%)

1.8

+0.09 (+5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-03 2025-03-03/bmo
Inst Owners71.69%
Inst Owner Change-77.99%
Ins Owners5.58%
Ins Owner Change-1.19%
Market Cap290.81M
Analysts84
Price Target16.9 (838.89%)
Short Float %8.87%
Short Ratio2.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.39%
Min EPS beat(2)-13.12%
Max EPS beat(2)2.34%
EPS beat(4)2
Avg EPS beat(4)-8.7%
Min EPS beat(4)-26.56%
Max EPS beat(4)2.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.86%
PT rev (3m)-29.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.76%
EPS NY rev (1m)0.62%
EPS NY rev (3m)-8.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.65
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.31%
ROE -91.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.51%
ROA(5y)N/A
ROE(3y)-47.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 845.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.98
Quick Ratio 10.98
Altman-Z 0.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1048.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.53%
EPS Next Y8.5%
EPS Next 2Y3.54%
EPS Next 3Y2.94%
EPS Next 5Y13.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.51%
EBIT Next 3Y-11.23%
EBIT Next 5Y20.11%
FCF growth 1Y-30.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.1%
OCF growth 3YN/A
OCF growth 5YN/A